Checkpoint Capital L.P. Has $2.78 Million Stock Position in TScan Therapeutics, Inc. $TCRX

Key Points

• Checkpoint Capital L.P. raised its holdings in TScan Therapeutics by 14.9%, now owning 2,017,650 shares valued at approximately $2.78 million, making it the firm's 10th largest investment.
• Institutional ownership is significant, with 82.83% of TScan Therapeutics shares held by institutions and hedge funds, indicating strong support from large investors.
• Analysts have mixed outlooks on the stock, with a consensus rating of "Buy" and a price target range from $7.00 to $10.00, suggesting potential upside despite recent market volatility.

Checkpoint Capital L.P. increased its stake in shares of TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) by 14.9% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 2,017,650 shares of the company's stock after acquiring an additional 261,663 shares during the period. TScan Therapeutics accounts for about 1.5% of Checkpoint Capital L.P.'s holdings, making the stock its 10th largest position. Checkpoint Capital L.P. owned about 3.57% of TScan Therapeutics worth $2,784,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. ProShare Advisors LLC bought a new position in shares of TScan Therapeutics in the fourth quarter valued at $40,000. Hsbc Holdings PLC bought a new stake in TScan Therapeutics in the first quarter worth approximately $49,000. Wells Fargo & Company MN grew its holdings in shares of TScan Therapeutics by 41.1% during the fourth quarter. Wells Fargo & Company MN now owns 19,540 shares of the company's stock valued at $59,000 after buying an additional 5,694 shares during the last quarter. Squarepoint Ops LLC bought a new position in shares of TScan Therapeutics during the fourth quarter valued at about $59,000. Finally, Heck Capital Advisors LLC bought a new position in TScan Therapeutics during the fourth quarter valued at about $61,000. 82.83% of the stock is currently owned by institutional investors and hedge funds.

TScan Therapeutics Stock Performance

TCRX traded down $0.05 during trading on Tuesday, hitting $1.84. 84,327 shares of the stock were exchanged, compared to its average volume of 444,808. The company has a quick ratio of 7.06, a current ratio of 7.06 and a debt-to-equity ratio of 0.18. The stock has a fifty day moving average price of $1.77 and a two-hundred day moving average price of $1.61. The firm has a market capitalization of $104.14 million, a P/E ratio of -1.68 and a beta of 1.00. TScan Therapeutics, Inc. has a 1-year low of $1.02 and a 1-year high of $6.23.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.28). TScan Therapeutics had a negative net margin of 1,964.88% and a negative return on equity of 63.33%. The business had revenue of $3.08 million for the quarter, compared to the consensus estimate of $1.31 million. As a group, sell-side analysts predict that TScan Therapeutics, Inc. will post -1.12 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on TCRX. Wedbush reissued an "outperform" rating and issued a $7.00 price target on shares of TScan Therapeutics in a report on Tuesday, August 12th. Wall Street Zen upgraded TScan Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, July 12th. Five equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $7.80.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.